Información*
| Nombre | ANA MARIA ESPINOSA GARCIA |
|---|---|
| Área | MEDICINA Y CIENCIAS DE LA SALUD |
| Campo | CIENCIAS MÉDICAS |
| Disciplina | BIOLOGÍA HUMANA |
| Especialidad | BIOLOGIA MOLECULAR |
| CVU | 121979 |
| Institución | |
|---|---|
| Dependencia | HOSPITAL GENERAL DE MEXICO "DR. EDUARDO LICEAGA" |
| Entidad | CIUDAD DE MEXICO |
| Nivel | 1 |
| Vigencia | Inicio: 01/01/2026 |
| Fin: 31/12/2030 |
* Información del primer trimestre de 2026.
Fuente: SECIHTI.
Publicaciones ORCID
- 2025
- Monitoring Inhibition of Hemoglobin Peroxidase Activity After Exposure to Cigarette Smoke Using an Electrochemical Biosensor Biosensors
- 2023
- Epstein‑Barr virus as a promoter of tumorigenesis in the tumor microenvironment of breast cancer (Review) International Journal of Molecular Medicine
- The mRNA and protein levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence, and risk of death in cervical cancer patients Cancer Medicine
- Potential Role of Protein Kinase FAM20C on the Brain in Raine Syndrome, an In Silico Analysis International Journal of Molecular Sciences
- El papel de los corticoesteroides en pacientes hospitalizados por COVID-19 en el Hospital General de México Cirugía y Cirujanos
- Validation of 3D-Printed Swabs for Sampling in SARS-CoV-2 Detection: A Pilot Study Annals of Biomedical Engineering
- CD3+/CD45+ concentric centrifugal figurate erythema as an unusual evanescent skin manifestation of COVID-19 International Journal of Dermatology and Venereology
- 2021
- A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.
- FAM20C Overview: Classic and Novel Targets, Pathogenic Variants and Raine Syndrome Phenotypes International Journal of Molecular Sciences
- 2020
- A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.